{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:43:02Z","timestamp":1790390582499,"version":"4.1.0"},"reference-count":113,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Musculoskeletal Australia Ph.D. Scholarship"},{"name":"Australian Government Research and Training Scholarship"},{"DOI":"10.13039\/100005646","name":"Actelion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"Glaxo Smith Kline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.berh.2019.101469","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T00:44:02Z","timestamp":1579567442000},"page":"101469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Systemic sclerosis: Advances towards stratified medicine"],"prefix":"10.1016","volume":"34","author":[{"given":"A.","family":"Quinlivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Proudman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.berh.2019.101469_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13075-019-1842-x","article-title":"Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study","volume":"21","author":"Park","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.berh.2019.101469_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.5301\/jsrd.5000239","article-title":"Early accrual of organ damage in systemic sclerosis: rationale for development of a disease damage index","volume":"2","author":"Tay","year":"2017","journal-title":"J\u00a0Scleroderma Relat Disord"},{"issue":"48","key":"10.1016\/j.berh.2019.101469_bib3","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008503","article-title":"Quantifying the direct public health care cost of systemic sclerosis: a comprehensive data linkage study","volume":"96","author":"Morrisroe","year":"2017","journal-title":"Medicine (Baltim)"},{"issue":"1","key":"10.1016\/j.berh.2019.101469_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/rheumatology\/kex362","article-title":"Work productivity in systemic sclerosis, its economic burden and association with health-related quality of life","volume":"57","author":"Morrisroe","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.berh.2019.101469_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.berh.2018.08.005","article-title":"Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis","volume":"32","author":"Ingegnoli","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2019.101469_bib6","doi-asserted-by":"crossref","first-page":"rky041","DOI":"10.1093\/rap\/rky041","article-title":"Risk factors for the development of systemic sclerosis: a systematic review of the literature","volume":"2","author":"Abbot","year":"2018","journal-title":"Rheumatol Adv Pract"},{"issue":"3","key":"10.1016\/j.berh.2019.101469_bib7","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10067-016-3533-1","article-title":"Occupational and environmental scleroderma. Systematic review and meta-analysis","volume":"36","author":"Rubio-Rivas","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2019.101469_bib8","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.semarthrit.2015.06.004","article-title":"Clinical peculiarities of patients with scleroderma exposed to silica: a systematic review of the literature","volume":"45","author":"Freire","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.berh.2019.101469_bib9","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/resp.13695","article-title":"Silica-associated lung disease: an old-world exposure in modern industries","volume":"24","author":"Barnes","year":"2019","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.berh.2019.101469_bib10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/03009742.2017.1299793","article-title":"There is a need for new systemic sclerosis subset criteria. A content analytic approach","volume":"47","author":"Johnson","year":"2018","journal-title":"Scand J Rheumatol"},{"issue":"11","key":"10.1016\/j.berh.2019.101469_bib11","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"10.1016\/j.berh.2019.101469_bib12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/annrheumdis-2019-eular.7164","article-title":"The very early diagnosis of systemic sclerosis (VEDOSS) project: predictors to develop definite disease from an international multicentre study","volume":"78","author":"Randone","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2019.101469_bib13","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.semarthrit.2018.02.005","article-title":"Does nailfold capillaroscopy help predict future outcomes in systemic sclerosis? A systematic literature review","volume":"48","author":"Paxton","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl 2","key":"10.1016\/j.berh.2019.101469_bib14","first-page":"65","article-title":"Preliminary analysis of nailfold capillaroscopy in the very early diagnosis of systemic sclerosis (VEDOSS): the CAPI-VEDOSS experience","volume":"78","author":"Cutolo","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2019.101469_bib15","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2019.101469_bib16","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.autrev.2018.02.008","article-title":"Predictors of morbidity and mortality in early systemic sclerosis: long-term follow-up data from a single-centre inception cohort","volume":"17","author":"Panopoulos","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.berh.2019.101469_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.5301\/jsrd.5000256","article-title":"What have multicentre registries across the world taught us about the disease features of systemic sclerosis?","volume":"2","author":"Proudman","year":"2017","journal-title":"J\u00a0Scleroderma Relat Disord"},{"issue":"8","key":"10.1016\/j.berh.2019.101469_bib18","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1136\/annrheumdis-2018-212999","article-title":"Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer","volume":"77","author":"Igusa","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2019.101469_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.semarthrit.2017.03.019","article-title":"Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis","volume":"47","author":"Hax","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2019.101469_bib20","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/annrheumdis-2018-213708","article-title":"Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts","volume":"78","author":"Volkmann","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2019.101469_bib21","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/art.22532","article-title":"Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors","volume":"57","author":"McNearney","year":"2007","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2019.101469_bib22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/rheumatology\/kes289","article-title":"Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease","volume":"52","author":"Moore","year":"2012","journal-title":"Rheumatology"},{"issue":"4 Suppl 91","key":"10.1016\/j.berh.2019.101469_bib23","first-page":"S111","article-title":"Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease","volume":"33","author":"Moore","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2019.101469_bib24","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.13-1474","article-title":"Predicting survival across chronic interstitial lung disease: the ILD-GAP model","volume":"145","author":"Ryerson","year":"2014","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.berh.2019.101469_bib25","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.chest.2017.06.009","article-title":"Mortality risk prediction in scleroderma-related interstitial lung disease: the SADL model","volume":"152","author":"Morisset","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.berh.2019.101469_bib26","series-title":"Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model","first-page":"1326","author":"Wu","year":"2018"},{"issue":"3","key":"10.1016\/j.berh.2019.101469_bib27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/BOR.0000000000000592","article-title":"Management of systemic sclerosis-associated interstitial lung disease","volume":"31","author":"Roofeh","year":"2019","journal-title":"Curr Opin Rheumatol"},{"issue":"10","key":"10.1016\/j.berh.2019.101469_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163894","article-title":"Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study","volume":"11","author":"Jaeger","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.berh.2019.101469_bib29","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/art.41020","article-title":"Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18","volume":"71","author":"Volkmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2019.101469_bib30","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/art.40815","article-title":"Performance of candidate serum biomarkers for systemic sclerosis-associated interstitial lung disease","volume":"71","author":"Elhai","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2019.101469_bib31","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/annrheumdis-2016-210236","article-title":"Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial","volume":"76","author":"Coghlan","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2019.101469_bib32","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1002\/art.38029","article-title":"Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis","volume":"65","author":"Lefevre","year":"2013","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2019.101469_bib33","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"Galie","year":"2015","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.berh.2019.101469_bib34","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1136\/hrt.2010.212084","article-title":"Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis","volume":"97","author":"Janda","year":"2011","journal-title":"Heart"},{"issue":"153","key":"10.1016\/j.berh.2019.101469_bib35","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0023-2019","article-title":"Screening for pulmonary arterial hypertension in systemic sclerosis","volume":"28","author":"Weatherald","year":"2019","journal-title":"Eur Respir Rev"},{"issue":"7","key":"10.1016\/j.berh.2019.101469_bib36","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","article-title":"Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study","volume":"73","author":"Coghlan","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2019.101469_bib37","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.semarthrit.2018.10.010","article-title":"Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension","volume":"48","author":"Young","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2019.101469_bib38","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1186\/ar3876","article-title":"N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study","volume":"14","author":"Thakkar","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.berh.2019.101469_bib39","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3899\/jrheum.180018","article-title":"Risk factors for mortality and cardiopulmonary hospitalization in systemic sclerosis patients at risk for pulmonary hypertension, in the PHAROS registry","volume":"46","author":"Hsu","year":"2019","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2019.101469_bib40","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/art.37838","article-title":"Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension","volume":"65","author":"Valerio","year":"2013","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2019.101469_bib41","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02148-2018","article-title":"An overview of the 6th world Symposium on pulmonary hypertension","volume":"53","author":"Galie","year":"2019","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.berh.2019.101469_bib42","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/rheumatology\/ket331","article-title":"Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension","volume":"53","author":"Ruiter","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.berh.2019.101469_bib43","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/annrheumdis-2014-205226","article-title":"Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database","volume":"74","author":"Maurer","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2019.101469_bib44","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2017-211912","article-title":"Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study","volume":"77","author":"Herrick","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2019.101469_bib45","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3899\/jrheum.121380","article-title":"The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review","volume":"40","author":"Muangchan","year":"2013","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2019.101469_bib46","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/art.40809","article-title":"Generation of a core set of items to develop classification criteria for scleroderma renal crisis using consensus methodology","volume":"71","author":"Butler","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2019.101469_bib47","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3899\/jrheum.171186","article-title":"Risk factors for future scleroderma renal crisis at systemic sclerosis diagnosis","volume":"46","author":"Gordon","year":"2019","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2019.101469_bib48","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.semarthrit.2013.09.008","article-title":"Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey","volume":"43","author":"Hudson","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2019.101469_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00403-018-1874-0","article-title":"Small intestinal bacterial overgrowth in systemic sclerosis: a review of the literature","volume":"311","author":"Polkowska-Pruszynska","year":"2019","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"10.1016\/j.berh.2019.101469_bib50","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/rheumatology\/key350","article-title":"Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality","volume":"58","author":"Richard","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.berh.2019.101469_bib51","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/acr.23479","article-title":"Determining the risk factors and clinical features associated with severe gastrointestinal dysmotility in systemic sclerosis","volume":"70","author":"McMahan","year":"2018","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"9","key":"10.1016\/j.berh.2019.101469_bib52","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/acr.23763","article-title":"Anti-RNPC-3 (U11\/U12) antibodies in systemic sclerosis in patients with moderate-to-severe gastrointestinal dysmotility","volume":"71","author":"McMahan","year":"2019","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"3","key":"10.1016\/j.berh.2019.101469_bib53","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.semarthrit.2019.05.005","article-title":"Evaluation of risk factors for pseudo-obstruction in systemic sclerosis","volume":"49","author":"Dein","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.berh.2019.101469_bib54","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2019.101469_bib55","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U","article-title":"Severe organ involvement in systemic sclerosis with diffuse scleroderma","volume":"43","author":"Steen","year":"2000","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2019.101469_bib56","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.semarthrit.2018.07.008","article-title":"Defining primary systemic sclerosis heart involvement: a scoping literature review","volume":"48","author":"Ross","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2019.101469_bib57","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1161\/01.CIR.53.3.483","article-title":"Myocardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction","volume":"53","author":"Bulkley","year":"1976","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.berh.2019.101469_bib58","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/0002-9343(69)90044-8","article-title":"Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls","volume":"46","author":"D'Angelo","year":"1969","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.berh.2019.101469_bib59","first-page":"882","article-title":"Primary myocardial disease in scleroderma-a comprehensive review of the literature to inform the UK Systemic Sclerosis Study Group cardiac working group","volume":"56","author":"Bissell","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.berh.2019.101469_bib60","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/ard.2008.103382","article-title":"Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis","volume":"69","author":"Allanore","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2019.101469_bib61","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1136\/annrheumdis-2019-215486","article-title":"Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study","volume":"78","author":"Valentini","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2019.101469_bib62","doi-asserted-by":"crossref","first-page":"183","DOI":"10.5301\/jsrd.5000244","article-title":"High sensitivity troponin might be a marker of subclinical scleroderma heart involvement: a preliminary study","volume":"2","author":"Barsotti","year":"2017","journal-title":"J\u00a0Scleroderma Relat Disord"},{"key":"10.1016\/j.berh.2019.101469_bib63","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejim.2018.10.013","article-title":"Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: a prospective study","volume":"60","author":"Bosello","year":"2019","journal-title":"Eur J Intern Med"},{"issue":"2 Suppl 71","key":"10.1016\/j.berh.2019.101469_bib64","first-page":"S81","article-title":"Role of N-terminal pro-brain natriuretic peptide in detecting clinically significant cardiac involvement in systemic sclerosis patients","volume":"30","author":"Chighizola","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2019.101469_bib65","first-page":"906","article-title":"The role of NT-proBNP in the diagnosis of ventricular arrhythmias in patients with systemic sclerosis","volume":"46","author":"Muresan","year":"2017","journal-title":"Iran J Public Health"},{"issue":"7","key":"10.1016\/j.berh.2019.101469_bib66","first-page":"1281","article-title":"Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis","volume":"22","author":"Clements","year":"1995","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2019.101469_bib67","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/MD.0b013e31829be125","article-title":"Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature","volume":"92","author":"Gelber","year":"2013","journal-title":"Medicine (Baltim)"},{"issue":"6","key":"10.1016\/j.berh.2019.101469_bib68","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3899\/jrheum.160574","article-title":"Antifibrillarin antibodies are associated with Native North American ethnicity and poorer survival in systemic sclerosis","volume":"44","author":"Mejia Otero","year":"2017","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2019.101469_bib69","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1136\/annrheumdis-2019-215145","article-title":"Predictors of disease worsening defined by progression of organ damage in diffuse\u00a0systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis","volume":"78","author":"Becker","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2019.101469_bib70","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1002\/art.39316","article-title":"Interpretation of an extended autoantibody profile in a well-characterized Australian systemic sclerosis (scleroderma) cohort using principal components analysis","volume":"67","author":"Patterson","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2019.101469_bib71","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/art.40906","article-title":"Phenotypes determined by cluster Analysis and their survival in the prospective European scleroderma trials and research cohort of patients with systemic sclerosis","volume":"71","author":"Sobanski","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2019.101469_bib72","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.humimm.2016.10.017","article-title":"Genomic and genetic studies of systemic sclerosis: a systematic review","volume":"78","author":"Chairta","year":"2017","journal-title":"Hum Immunol"},{"key":"10.1016\/j.berh.2019.101469_bib73","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jaut.2017.05.004","article-title":"Unfolding the pathogenesis of scleroderma through genomics and epigenomics","volume":"83","author":"Tsou","year":"2017","journal-title":"J\u00a0Autoimmun"},{"issue":"6","key":"10.1016\/j.berh.2019.101469_bib74","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/art.40455","article-title":"Skin gene expression is prognostic for the trajectory of skin disease in patients with diffuse cutaneous systemic sclerosis","volume":"70","author":"Stifano","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"21","key":"10.1016\/j.berh.2019.101469_bib75","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89073","article-title":"Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity","volume":"1","author":"Lofgren","year":"2016","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.berh.2019.101469_bib76","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13073-017-0417-1","article-title":"A\u00a0novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis","volume":"9","author":"Taroni","year":"2017","journal-title":"Genome Med"},{"issue":"5","key":"10.1016\/j.berh.2019.101469_bib77","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jid.2016.12.007","article-title":"A\u00a0functional genomic meta-analysis of clinical trials in systemic sclerosis: toward precision medicine and combination therapy","volume":"137","author":"Taroni","year":"2017","journal-title":"J\u00a0Investig Dermatol"},{"issue":"11","key":"10.1016\/j.berh.2019.101469_bib78","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1002\/art.39287","article-title":"A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis","volume":"67","author":"Rice","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2019.101469_bib79","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/art.40243","article-title":"Earliest phase of systemic sclerosis typified by increased levels of inflammatory proteins in the serum","volume":"69","author":"Cossu","year":"2017","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2019.101469_bib80","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3899\/jrheum.160833","article-title":"Proteomic analysis of sera from individuals with diffuse cutaneous systemic sclerosis reveals a multianalyte signature associated with clinical improvement during imatinib mesylate treatment","volume":"44","author":"Haddon","year":"2017","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2019.101469_bib81","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41584-018-0021-9","article-title":"Existing and novel biomarkers for precision medicine in systemic sclerosis","volume":"14","author":"Wermuth","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2019.101469_bib82","first-page":"421","article-title":"The challenges and controversies of measuring disease activity in systemic sclerosis","volume":"3","author":"Ross","year":"2018","journal-title":"J\u00a0Scleroderma Relat Disord"},{"issue":"1","key":"10.1016\/j.berh.2019.101469_bib83","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2016-209768","article-title":"The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index","volume":"76","author":"Valentini","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.101469_bib84","article-title":"The scope and consistency of outcomes reported in trials in patients with systemic sclerosis","author":"Sumpton","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.berh.2019.101469_bib85","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/art.39501","article-title":"The American College of Rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis","volume":"68","author":"Khanna","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2019.101469_bib86","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/annrheumdis-2018-214764","article-title":"Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis","volume":"78","author":"Ferdowsi","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2019.101469_bib87","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.semarthrit.2019.01.007","article-title":"Damage indices in rheumatic diseases: a systematic review of the literature","volume":"49","author":"Ferdowsi","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2019.101469_bib88","doi-asserted-by":"crossref","first-page":"188","DOI":"10.5301\/jsrd.5000243","article-title":"Validity of the PROMIS-29 in a large Australian cohort of patients with systemic sclerosis","volume":"2","author":"Morrisroe","year":"2017","journal-title":"J\u00a0Scleroderma Relat Disord"},{"issue":"5","key":"10.1016\/j.berh.2019.101469_bib89","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.semarthrit.2016.10.002","article-title":"Systematic review of systemic sclerosis-specific instruments for the EULAR Outcome Measures Library: an evolutional database model of validated patient-reported outcomes","volume":"46","author":"Ingegnoli","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2019.101469_bib90","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.rdc.2016.01.003","article-title":"Patient-reported outcome measures in systemic sclerosis (scleroderma)","volume":"42","author":"Pellar","year":"2016","journal-title":"Rheum Dis Clin N Am"},{"issue":"1","key":"10.1016\/j.berh.2019.101469_bib91","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13075-019-1889-8","article-title":"Autologous hematopoietic stem cell transplantation in systemic sclerosis induces long-lasting changes in B cell homeostasis toward an anti-inflammatory B cell cytokine pattern","volume":"21","author":"Gernert","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.berh.2019.101469_bib92","first-page":"944","article-title":"Analysis of immune reconstitution after autologous CD34+ stem\/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4+ T cells","author":"Hiroshi","year":"2011","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.berh.2019.101469_bib93","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.bbmt.2018.01.020","article-title":"Autologous hematopoietic stem cell transplantation for systemic sclerosis: a systematic review and meta-analysis","volume":"24","author":"Shouval","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.berh.2019.101469_bib94","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13075-019-1823-0","article-title":"CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I\/II clinical trial conducted in Japan","volume":"21","author":"Ayano","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.berh.2019.101469_bib95","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bjd.15993","article-title":"Efficacy and safety of autologous haematopoietic stem cell transplantation in systemic sclerosis: a systematic review of the literature","volume":"178","author":"Eyraud","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2019.101469_bib96","first-page":"1","article-title":"Comparative efficacy and safety of immunosuppressive therapies for systemic sclerosis related interstitial lung disease: a Bayesian network analysis","author":"Zheng","year":"2019","journal-title":"Mod Rheumatol"},{"issue":"10","key":"10.1016\/j.berh.2019.101469_bib97","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3899\/jrheum.180441","article-title":"Cyclophosphamide for systemic sclerosis-related interstitial lung disease: a comparison of scleroderma lung study I and II","volume":"46","author":"Volkmann","year":"2019","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2019.101469_bib98","article-title":"Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis","author":"Hoa","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.berh.2019.101469_bib99","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.berh.2019.101469_bib100","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/1346-8138.15079","article-title":"Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease","volume":"46","author":"Ebata","year":"2019","journal-title":"J\u00a0Dermatol"},{"issue":"7","key":"10.1016\/j.berh.2019.101469_bib101","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"26","key":"10.1016\/j.berh.2019.101469_bib102","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.berh.2019.101469_bib103","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.berh.2019.101469_bib104","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3899\/jrheum.180595","article-title":"Longterm efficacy and safety of monotherapy versus combination therapy in systemic sclerosis-associated pulmonary arterial hypertension: a retrospective RESCLE registry study","volume":"47","author":"Pestana-Fernandez","year":"2020","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2019.101469_bib105","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.autrev.2015.01.018","article-title":"Fecal calprotectin in systemic sclerosis and review of the literature","volume":"14","author":"Marie","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.berh.2019.101469_bib106","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/rheumatology\/key175","article-title":"Treatment of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review","volume":"57","author":"Pittman","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2019.101469_bib107","article-title":"Effectiveness of Saccharomyces boulardii and metronidazole for small intestinal bacterial overgrowth in systemic sclerosis","author":"Garcia-Collinot","year":"2019","journal-title":"Dig Dis Sci"},{"issue":"suppl 10","key":"10.1016\/j.berh.2019.101469_bib108","article-title":"Riociguat in patients with early diffuse systemic sclerosis: a randomized, double-blind, placebo-controlled phase IIb study (RISE-SSc) (abstract 903)","volume":"70","author":"Distler","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 10","key":"10.1016\/j.berh.2019.101469_bib109","article-title":"Efficacy and safety of tocilizumab for the treatment of systemic sclerosi: results from a phase 3 randomized controlled trial (abstract 898)","volume":"70","author":"Khanna","year":"2018","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2019.101469_bib110","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis - results of a phase 2 investigator-initiated, multicenter, double-blind randomized placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2019.101469_bib111","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2019.101469_bib112","first-page":"106","article-title":"UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis","volume":"34","author":"Lynch","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.berh.2019.101469_bib113","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1002\/art.39718","article-title":"Nailfold videocapillaroscopic features and other clinical risk factors for digital ulcers in systemic sclerosis: a multicenter, prospective cohort study","volume":"68","author":"Cutolo","year":"2016","journal-title":"Arthritis Rheumatol"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694219301652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694219301652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:19:47Z","timestamp":1761499187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694219301652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":113,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1521694219301652"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2019.101469","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic sclerosis: Advances towards stratified medicine","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2019.101469","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2019 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101469"}}